Number needed to treat: a descriptor for weighing therapeutic options.
OBJECTIVE
The utility and limitations of the number needed to treat (NNT) are described and compared with those of alternative descriptors of therapeutic yield.


CONCLUSIONS
Pharmacists, physicians, and patients are more likely to launch interventions based on relative measures of therapeutic yield. The NNT is a simple way to express the absolute therapeutic yield of an intervention. It is essential to take baseline risk and length of follow-up into account when calculating and interpreting absolute or relative measures of therapeutic yield. Patients may have difficulty understanding what the NNT tells them about the benefits and harms associated with an intervention, and confidence intervals for the NNT can be difficult to interpret. Relative measures of benefits are advantageous for comparing benefits across populations with different risks. The use of absolute measures to describe therapeutic options leads to more conservative decision-making and is potentially more useful. Among the absolute measures, the absolute risk reduction may be easier to understand than the NNT. These measures are most helpful when the best options are not clear or when patient input is needed. Personal digital assistants and Web-based tools can assist with calculations.


CONCLUSIONS
The NNT is a useful measure but is influenced by numerous variables and may not be easily understood by patients.
Wen
Lonnie
L
South Texas Veterans Health Care System (STVHCS), San Antonio, TX, USA. k.wen@pfizer.com
Badgett
Robert
R
Cornell
John
J
D000465:Algorithms; D002986:Clinical Trials as Topic; D004358:Drug Therapy / Q000706:statistics & numerical data*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D019095:Point-of-Care Systems; D018570:Risk Assessment; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D019821:Simvastatin / Q000627:therapeutic use; D016019:Survival Analysis
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin